Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1038
Abstract: Pemigatinib is a fibroblast growth factor receptor 1–3 inhibitor used to treat cholangiocarcinoma. A compartmental population pharmacokinetics model was developed using data from 318 patients with cancer enrolled in a phase 1 dose‐escalation/dose‐expansion study, a… read more here.
Keywords: pharmacokinetics analysis; typical pemigatinib; population pharmacokinetics; model ... See more keywords
Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or Hip
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1380
Abstract: Osteoarthritis (OA) pain management options are currently limited. Fasinumab, an anti‐nerve growth factor monoclonal antibody, has been investigated in healthy volunteers and patients with OA‐related pain, among other conditions. Data from 12 Phase I‐III clinical… read more here.
Keywords: pharmacokinetics fasinumab; healthy volunteers; volunteers patients; population pharmacokinetics ... See more keywords
Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.419
Abstract: Desvenlafaxine exposure in Korean and US populations was compared using population pharmacokinetic (PK) analysis. Data from a single‐ and multiple‐dose study of desvenlafaxine (50, 100, and 200 mg) in 30 healthy Korean subjects were added… read more here.
Keywords: pharmacokinetics desvenlafaxine; korean subjects; desvenlafaxine pharmacokinetics; model ... See more keywords
Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR‐Mutated Advanced NSCLC
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.3759
Abstract: Osimertinib, a third‐generation, central nervous system‐active epidermal growth factor receptor‐tyrosine kinase inhibitor, potently and selectively inhibits epidermal growth factor receptor‐tyrosine kinase inhibitor sensitizing and T790M resistance mutations, with efficacy in epidermal growth factor receptor‐mutated non‐small… read more here.
Keywords: first line; factor receptor; mutated advanced; growth factor ... See more keywords
Parametric Approaches in Population Pharmacokinetics.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.1633
Abstract: Population pharmacokinetic (popPK) approaches have spread widely throughout clinical pharmacology research, and every clinician should have some understanding of them. After a general introduction on the fundamentals and fields of application of these approaches, this… read more here.
Keywords: approaches population; pharmacology; population pharmacokinetics; parametric approaches ... See more keywords
Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2055
Abstract: We characterized the population pharmacokinetics of anifrolumab, a type I interferon receptor–blocking antibody. Pharmacokinetic data were analyzed from the anifrolumab (intravenous [IV], every 4 weeks) arms from 5 clinical trials in patients with systemic lupus… read more here.
Keywords: pharmacokinetics anifrolumab; healthy volunteers; patients systemic; population pharmacokinetics ... See more keywords
Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID‐19) in India
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2092
Abstract: Healthcare workers (HCWs) and frontline workers were recommended hydroxychloroquine (HCQ) 400 mg twice a day on day 1, followed by 400 mg once weekly for the next 7 weeks, as prophylaxis against COVID‐19. There was… read more here.
Keywords: covid; pharmacokinetics hydroxychloroquine; healthcare workers; population pharmacokinetics ... See more keywords
Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2137
Abstract: Patritumab deruxtecan is an antibody–drug conjugate consisting of a fully human monoclonal antibody against human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a tetrapeptide‐based cleavable linker. As part… read more here.
Keywords: clearance; patritumab deruxtecan; dxd; population pharmacokinetics ... See more keywords
Population Pharmacokinetics of Tacrolimus in Umbilical Cord Blood Transplant Pediatrics.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2162
Abstract: Tacrolimus was frequently used in umbilical cord blood transplant (UCBT) pediatrics for prevention of graft-vs-host disease (GVHD). The aim of the present study was to evaluate the population pharmacokinetics (PPK) of tacrolimus among UCBT pediatrics… read more here.
Keywords: blood transplant; umbilical cord; cord blood; pharmacokinetics tacrolimus ... See more keywords
Population Pharmacokinetics of Monalizumab in Patients with Advanced Solid Tumors.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2220
Abstract: Monalizumab is a novel, first-in-class humanized immunoglobulin G (IgG)-4 monoclonal antibody (mAb) immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors. The objectives of this analysis were to develop a population pharmacokinetic (PK) model of… read more here.
Keywords: volume distribution; patients advanced; population pharmacokinetics; solid tumors ... See more keywords
Population pharmacokinetics of haloperidol in terminally ill adult patients
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Clinical Pharmacology"
DOI: 10.1007/s00228-017-2283-6
Abstract: PurposeOver 80% of the terminally ill patients experience delirium in their final days. In the treatment of delirium, haloperidol is the drug of choice. Very little is known about the pharmacokinetics of haloperidol in this… read more here.
Keywords: ill patients; terminally ill; pharmacokinetics haloperidol; population pharmacokinetics ... See more keywords